378
Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological MRI follow-up of low-grade
glioma: a plead for systematic measurement of growth rates. Neurosurgery. 2012;71:729–40.
Park S, Hatanpaa KJ, Xie Y, et al. The receptor interacting protein 1 inhibits p53 induction through
NF-{kappa}B activation and confers a worse prognosis in glioblastoma. Cancer Res.
2009a;69:2809–16.
Park Y, Freedman AN, Gail MH, et al. Validation of a colorectal cancer risk prediction model
among whites 50 years old and over. J Clin Oncol. 2009b;27:694–8.
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrin-
sic subtypes. J Clin Oncol. 2009;27:1160–7.
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma
multiforme. Science. 2008;321:1807–12.
Patil R, Clifton GT, Holmes JP, et al. Clinical and immunologic responses of HLA-A3+ breast
cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II
clinical trial. J Am Coll Surg. 2010;210:140–7.
Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specifi c cancer immunotherapeutic.
Immunotherapy. 2009;1:19–25.
Perez SA, von Hofe E, Kallinteris NL, et al. A new era in anticancer peptide vaccines. Cancer.
2010;116:2071–80.
Pernemalm M, De Petris L, Branca RM, et al. Quantitative proteomics profi ling of primary lung
adenocarcinoma tumors reveals functional perturbations in tumor metabolism. J Proteome Res.
2013;12:3934–43.
Perreard L, Fan C, Quackenbush JF, et al. Classifi cation and risk stratifi cation of invasive breast
carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006;8:R23.
Petty RD, Kerr KM, Murray GI, et al. Tumor transcriptome reveals the predictive and prognostic
impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol.
2006;24:1729–44.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy
in HER2-positive breast cancer. NEJM. 2005;353:1659–72.
Pierceall WE, Kornblau SM, Carlson NE, et al. BH3 profi ling discriminates response to cytarabine-
based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013;12:2940–9.
Pilla L, Rivoltini L, Patuzzo R, et al. Multipeptide vaccination in cancer patients. Expert Opin Biol
Ther. 2009;9:1043–55.
Polo JM, Juszczynski P, Monti S, et al. Transcriptional signature with differential expression of
BCL6 target genes accurately identifi es BCL6-dependent diffuse large B cell lymphomas. Proc
Natl Acad Sci U S A. 2007;104:3207–12.
Pradeep S, Kim SW, Wu SY, et al. Hematogenous metastasis of ovarian cancer: rethinking mode
of spread. Cancer Cell. 2014;26:77–91.
Predina J, Eruslanov E, Judy B, et al. Changes in the local tumor microenvironment in recurrent
cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A.
2013;110:E415–24.
Press RD, Kamel-Reid S, Ang D. BCR-ABL1 RT-qPCR for monitoring the molecular response to
tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagn. 2013;15:565–76.
Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adju-
vant chemotherapy. NEJM. 2006;354:2103–11.
Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cra-
nial irradiation. NEJM. 2009;360:2730–41.
Puzanov I, Flaherty KT. Targeted molecular therapy in melanoma. Semin Cutan Med Surg.
2010;29:196–201.
Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the
stress response to ROS. Nature. 2011;475:231–4.
Ratner ES, Keane FK, Lindner R, et al. A KRAS variant is a biomarker of poor outcome, platinum
chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene.
2012;31:4559–66.
Reinis M. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas. Curr Opin Mol
Ther. 2008;10:526–34.
10 Personalized Therapy of Cancer